KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBT Margin (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed EBT Margin for 10 consecutive years, with 1.7% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 754.0% year-over-year to 1.7%, compared with a TTM value of 7.09% through Dec 2025, up 1485.0%, and an annual FY2025 reading of 7.09%, up 1485.0% over the prior year.
  • EBT Margin was 1.7% for Q4 2025 at Teva Pharmaceutical Industries, down from 14.42% in the prior quarter.
  • Across five years, EBT Margin topped out at 14.42% in Q3 2025 and bottomed at 30.64% in Q2 2022.
  • Average EBT Margin over 5 years is 4.4%, with a median of 1.3% recorded in 2021.
  • The sharpest move saw EBT Margin surged 12192bps in 2021, then tumbled -3849bps in 2022.
  • Year by year, EBT Margin stood at 4.27% in 2021, then crashed by -615bps to 30.51% in 2022, then surged by 135bps to 10.61% in 2023, then plummeted by -155bps to 5.84% in 2024, then surged by 129bps to 1.7% in 2025.
  • Business Quant data shows EBT Margin for TEVA at 1.7% in Q4 2025, 14.42% in Q3 2025, and 4.86% in Q2 2025.